Z1332 its more art than science and when revenues finally start...

Z1332 its more art than science and when revenues finally start flowing it will depend on how fast and what the projected revenue growth numbers are.

You need to try and work out Earnings per share and then you can multply that by the sector average to get an indea. The hard part is of course deteriining the earnings per share. The S&P/ASX Australian Healthcare average Price Eanings is 40.71 (Commsec) with NEU (16.2), CUV (22.59) and CSL (41.24).
We have done numbers previously which even with the current dilluation are amazing just due to the size of the market. So if we can become 1st Line thearapy it could still be a big number.

So if you earned $1 per share times that by the sector average and you would get $40 per share.

With the current position of the company its really going to come down to:
1. The size of the next capital raise and its dilutive affect
2. How many more performance shares PR decides throw around
3. How long it takes to ramp up sales
4. How much the treatment sells for
5. What royalty we negotiate.

When this thing finally gets FDA approval you will get a FOMO affect which may be the best price you will get for a while as ultimately once the approvals come its then time to turn the bluesky into revenues. CUV for example hit $45 on FDA approval and it has been ranging between $15 - $25 for a long time after. So you could have sold into the approval and then repurchased for 1/3 of the price....

The way PAR work however is on good news it drops so FDA approval will see us near ($0) that or PR's stella capital managment will leave us (and himself) heavly. But he has solved that little problem by giving himself more performance shares. (For those interested take a look at RAC's recent capital raising it was a cracker and very favourable to long term shareholders who have supported the company).

The Pool